|Bid||201.40 x 800|
|Ask||201.69 x 800|
|Day's Range||196.88 - 202.32|
|52 Week Range||83.37 - 203.64|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
10x Genomics (NASDAQ: TXG), which is focused on helping researchers study genomic changes on a cellular level, beat Wall Street expectations in the first quarter, but shares of the company fell substantially. In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss why the share price dropped and why the short-term move shouldn't affect long-term investors. Brian Orelli: Not every company had an impressive first quarter.
10x Genomics Inc Cl A shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.